Anti-IMPAD1 antibody produced in rabbit，100UL，HPA009411-100UL，Sigma

General description

IMPAD1 (inositol monophosphatase domain containing 1) is a nucleotide phosphatase which is localized to Golgi, and hence, is also called Golgi-resident PAP phosphatase (gPAPP). This gene is localized to human chromosome 8. This protein was first identified in metazoan genome, and is composed of a single transmembrane domain. It is a type II transmembrane protein.

Immunogen

myo-inositol monophosphatase A3 recombinant protein epitope signature tag (PrEST)

Application

All Prestige Antibodies Powered by Atlas Antibodies are developed and validated by the Human Protein Atlas (HPA) project and as a result, are supported by the most extensive characterization in the industry.

The Human Protein Atlas project can be subdivided into three efforts: Human Tissue Atlas, Cancer Atlas, and Human Cell Atlas. The antibodies that have been generated in support of the Tissue and Cancer Atlas projects have been tested by immunohistochemistry against hundreds of normal and disease tissues and through the recent efforts of the Human Cell Atlas project, many have been characterized by immunofluorescence to map the human proteome not only at the tissue level but now at the subcellular level. These images and the collection of this vast data set can be viewed on the Human Protein Atlas (HPA) site by clicking on the Image Gallery link. We also provide Prestige Antibodies^® protocols and other useful information.

Biochem/physiol Actions

In mice, IMPAD1 (inositol monophosphatase domain containing 1) inactivation is linked with skeletal dysplasia and abnormal joint formation. It hydrolyzes the byproduct of sulfotransferase ractions, phosphoadenosine phosphate (PAP) to AMP. In human, the deficiency of this enzyme is linked with chondrodysplasia, which is a skeletoarticular disorder linked with defective synthesis of sulfated proteoglycans. Mutations in this gene are linked with short stature, joint dislocations, brachydactyly and cleft palate in patients with Desbuquois dysplasia type 1. Mutations in IMPAD1 are also associated with Catel-Manzke syndrome, the patients of which show hyperphalangism with index fingers demonstrating bilateral deviation, and micrognathia with or without cleft palate. In vitro this protein is inhibited by lithium, and mice with IMPAD1 inactivation show neonatal fatality lung aberrations similar to atelectasis, and dwarfism characterized by abnoraml cartilage structure. This protein might be involved in endochondral ossification, thus, playing a part in formation of skeletal elements.

Features and Benefits

Prestige Antibodies^® are highly characterized and extensively validated antibodies with the added benefit of all available characterization data for each target being accessible via the Human Protein Atlas portal linked just below the product name at the top of this page. The uniqueness and low cross-reactivity of the Prestige Antibodies^® to other proteins are due to a thorough selection of antigen regions, affinity purification, and stringent selection. Prestige antigen controls are available for every corresponding Prestige Antibody and can be found in the linkage section.

Every Prestige Antibody is tested in the following ways:

• IHC tissue array of 44 normal human tissues and 20 of the most common cancer type tissues.
• Protein array of 364 human recombinant protein fragments.

Physical form

Solution in phosphate-buffered saline, pH 7.2, containing 40% glycerol and 0.02% sodium azide

Other Notes

Corresponding Antigen APREST71722

Legal Information

Prestige Antibodies is a registered trademark of Merck KGaA, Darmstadt, Germany